ODAC September 13th, 2005 Tarceva® (erlotinib) Adrian Senderowicz, M.D. DDODP, CDER FDA sNDA 21,743 Tarceva® (erlotinib) Applicantâs Proposed Indication: âTARCEVA®…

KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer treated with FOLFIRI with or without cetuximab: The CRYSTAL experience…

KRAS status and efficacy in the first-line treatment of patients with mCRC treated with FOLFOX with or without cetuximab: The OPUS experience Carsten Bokemeyer* I Bondarenko,…

ASH Highlights, 2007: Lymphoma Lawrence D. Kaplan MD UCSF ASH 2007 Highlights: Lymphoma No. Topic R-Bendamustine vs R-CHOP for indolent NHL LB-1 Intensive immunochemotherapy…

KRAS status and efficacy in the first-line treatment of patients with mCRC treated with FOLFOX with or without cetuximab: The OPUS experience Carsten Bokemeyer* I Bondarenko,…

AVADO TRIAL David Miles Mount Vernon Cancer Centre, Middlesex, United Kingdom A randomized, double-blind study of bevacizumab in combination with docetaxel as first-line…

Right Patient, Right Treatment: Insights in EGFR Mutation-positive NSCLC Professor Martin Schuler MD West German Cancer Center Essen, Germany Right patient, right treatment:…

A randomized trial of gemcitabine vs. gemcitabine plus cisplatin in chemotherapy-naïve advanced pancreatic carcinoma. The GIP-1 (Gruppo Italiano Pancreas – GOIM/GISCAD/GOIRC)…

Management of Ascites Ascites in Cirrhosis AASLD guidelines 2012 update Ascites 80% CLD, 5% mixed, 15% other Important landmark - poor prognosis 19% 1 year mortality 44%…

sNDA 20-571 “Irinotecan as a component of first line treatment of patients with metastatic colorectal cancer.” APPROVED SCHEDULES (SINGLE AGENT) 125 mg/m2 wkly x 4 Q6…